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Regenerative medicine is a pioneering field aimed at restoring and regenerating the function of damaged cells, organs and tissues
in order to establish normal function. It demands the cross communication of disciplines to develop eﬀective therapeutic stem
cell based therapies. Nanotechnology has been instrumental in the development and translation of basic research to the clinically
relevant therapies. In particular, magnetic nanoparticles (MNPs) have been applied to tag, track and activate stem cells oﬀering
an eﬀective means of monitoring in vitro and in vivo behaviour. MNPs are comprised of an iron oxide core with a biocompatible
biological polymer. Safety is an issue of constant concern and emphasises on the importance of investigating the issue of toxicity.
Any indication of toxicity can ultimately limit the therapeutic eﬃciency of the therapy. Toxicity is highly dependent on the physical,
chemical and structural properties of the MNP itself as well as dose and intended use. Few in vitro studies have reported adverse
eﬀects of MNP on cells at in vitro in therapeutic doses. However, long term in vivo studies have not been studied as extensively.
This review aims to summarise current research in this topic highlighting commonly used toxicity assays to investigate this.
1. Introduction
Nanotechnology is an emerging field with growing interest
for its numerous applications ranging from information
technologies to medicinal applications [1]. Subsequent social
and economic implications of this field have resulted in its
increased popularity and demand with a competitive drive
[2]. It is heavily dependent upon the cross-collaboration
of various scientific disciplines to manipulate and alter the
dimensions of materials at an atomic scale resulting in the
formation of nanomaterials [1]. Nanomaterials are defined
as materials with one, two, or three external dimensions
ranging from 1 to 100 nm—the nanoscale [2, 3].
Recently, nanoscale materials have been the centre of
research, particularly in the fields of regenerative medicine
and tissue engineering. Examples include nanoparticles,
nanofibers, and nanotubes, all of which can be specifically
tailored to their role and function within tissue engineering
[4]. Nanoscale materials in these forms have been used in
conjunction with stem cells to produce stem cell-based thera-
pies with emphasis on replacing and restoring the function of
cells, tissues, or organs in order to establish normal function
[5]. Examples include the transplantation of mesenchymal
stem cells for the treatment of Huntington’s disease [6].
This paper will focus specifically on the implications of
applying nanoparticles in regenerative medicine and tissue
engineering.
A nanoparticle can be defined as a material with three
external dimensions of equal nanoscale dimensions [2]. The
major benefit of using nanoparticles is that, due to their
size, they can be accurately manoeuvred and targeted to a
specific biological entity or marker [7] and interact on a
cellular (10–100 nm), subcellular (20–250 nm), protein (3–
50 nm), or genetic scale (10–100 nm) [8, 9]. Their unique,
electronic, optical, and magnet properties coupled with
their specific dimensions have furthered their attractiveness
in this field [10–12]. Furthermore, nanoparticles can be
customised for a specific biological purpose such as cell
isolation, drug delivery, diagnostics (magnetic resonance
imaging MRI), cellular imaging, and hyperthermia [8, 11,
13–15]. Examples of nanoparticles include quantum dots
and magnetic nanoparticles (MNPs) [12, 16]. Magnetic
nanoparticles will be the main focus of this paper.
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1.1. Magnetic Nanoparticles (MNPs). Magnetic nanoparti-
cles have a particle size within the nanoscale with magnetic
properties. Various metals can be used to convey the mag-
netic properties of MNPs; nickel, cobalt, and iron have
demonstrated to be such examples. Organic and inorganic
polymers including RGD peptides, fibronectin, and dex-
tran can be used to coat the magnetic core resulting in
improved biocompatibility by protecting biological entities
from adverse toxic reactions [14, 17]. The customisation of
surface coatings to desired specifications can be achieved
via surface charge alterations, protein-binding capacity, and
surface topography [18]; this increases functionalization
of the particles encouraging enhanced interaction with
biological entities, with minimal toxic eﬀects [8, 11]. Addi-
tional factors that can further influence the behaviour of
MNPs are the size [19] and magnetisation (paramagnetic,
ferromagnetic, ferromagnetic, and superparamagnetic) of
the particles themselves [20].
Before nanoparticles can be considered for the use in
regenerative medicine, they must fulfil the following speci-
fications.
Specifications:
(i) biocompatible that is nontoxic to the cells [21–23],
(ii) biodegradable [22, 24],
(iii) maintain physical properties after surface modifica-
tion [11],
(iv) must not aﬀect stem cell characteristics [21],
(v) eﬀective at therapeutic doses [21, 22],
(vi) ideally have regulatory approval [20],
(vii) minimal or no transfer of by-products to surround-
ing tissue/cells [22, 25],
(viii) chemically stable in physiological conditions [24].
MNPs for the use in biomedical applications are desired
to exhibit superparamagnetic properties (SPIONs) [26].
SPIONs are typically small particles composed of either
a magnetite (Fe3O4) or maghemite (γ-Fe2O3) core [20,
27] coated with a biocompatible organic/inorganic polymer
[17, 28] or precipitated throughout a porous biocompatible
polymer [10, 20]. Both maghemite and magnetite are tradi-
tionally ferromagnetic in nature. However, as they decrease
in size to 30 nm or smaller, they lose their permanent
magnetism and become superparamagnetic [2]. Iron (Fe)
oxide-based MNPs are suitable for biological application for
the following reasons: the superparamagnetic nature implies
that the particles will not be attracted to each other, and so
the risk of agglomeration in a medical setting is minimised
[23]. Fe is a naturally occurring metal in the human
body (ferritin), and hence iron-containing nanoparticles are
biocompatible as the body is adapted to metabolising the
particles into its elements; these can be utilised by the body
in subsequent metabolic processes [19, 29–32].
The precedent for using SPIONs in regenerativemedicine
comes from the application of SPION-based magnetic
resonance imaging (MRI) contrast agents [33] which are
accepted T2 weighted contrast agents [26]. MR imaging is a
safe and eﬀective noninvasive means of imaging anatomical
tissue [34]. It is thought that these contrast agents can be
used for a variety of purposes in the clinical translation
of stem cell-based therapies for the tagging, tracking, and
activation of stem cells and other cell types [26, 29, 35].
Feridex (USA), also referred to as Endorem (EU) is example
of FDA-approved, iron-based MRI contrast agent which
has recently been taken oﬀ the market [20, 36]. These
particles have an iron oxide core and are between 50 and
180 nm in diameter with an overall negative charge along
with biodegradable and biocompatible properties [20, 32].
The dextran coating prevents the coagulation of particles;
however a limitation to using dextran is its inability to enable
the eﬃcient uptake of these particles by cells. In these cases,
transfection agents may be required.
The high resolution and impressive tissue penetration
depth attributed to SPION-based MRI contrast agents
has not only driven diagnostics to higher levels but also
encouraged themultidisciplinary applications of these agents
in fields such as regenerative medicine. These agents are,
however, limited by their poor sensitivity thus preventing
microscopic examination of tissue over time which is a
crucial requirement in the development of stem cell-based
therapies [12]. Other imaging modalities such as positive
emission topography (PET scan), X-ray, ultrasound, and
computed tomography (CT) [34] (available in a clinical
setting) oﬀer greater sensitivity in some cases but are lacking
in other aspects such as the use of radioisotopes which
could result in detrimental side eﬀects in the case of PET
scans [34]. This has therefore encouraged the integration
of imaging modalities [12, 34, 37] and, as a consequence,
the development of multifunctional nanoparticles to be used
in conjunction with various imaging techniques. In the
context of regenerative medicine, this could further our
understanding of biological processes related to stem cell-
based therapies [12, 26]. Unlike individual nanoparticles,
multifunctional nanoparticles exploit the benefits of the
imaging modalities of choice while minimising the disad-
vantages. In many instances this is translated in enhanced
cellular tracking with high special resolution and high
anatomical contrast without the issues of ionizing radiation
for extended periods of time [12, 26, 37].
1.2.Multifunctional Nanoparticles. The development ofmul-
tifunctional nanoparticles requires the reengineering and
modification of particle surfaces to meet a greater variety of
applications. It is highly desirable to incorporate fluorescent
properties, near infrared absorption, and photon scattering,
all of which enable in vivo imaging to a greater extent. This
however is no easy task. It is a highly challenging task to
incorporate the properties that make a particle a good MRI
contrast agent and those that allow good NIR response, for
example [12]. It involves novel and intricate approaches to
achieve all the desired characteristics. In a study by Jin et al.,
the surface of nanoparticles was coated with gold (a noble
metal) [12] in an eﬀort to expand on the multifunctional
aspect of MNP and incorporate near infrared absorption and
photon scattering properties. This group successfully created
smooth particles with the core spatially separated from the
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Figure 1: Schematic diagram highlighting the use of SPIONs in regenerative medicine. Cells requires the internalisation of SPIONS. Labelled
cells are then implanted within the body and visualised by MRI [52].
shell thus resulting in uniform gold-coated MNP while still
maintaining dimensions, electronic, magnetic, and thermal
properties and still being responsive to NIR spectra [12].
Mahmoudi et al. took this one step further and created gold-
coated magnetic nanoparticles with jagged edges to allow for
ramen spectroscopy to be employed and in this way imaging
at the molecular level [26]. In another study, Mahmoudi and
Shokrgozar sought to add to the multifunctionality of these
particles by adding and trapping a fluorescent polymeric dye
between the core and the gold coating [37]. This simple
addition adds an extra imaging modality for either in vivo
or in vitro imaging.
1.3. Application of SPIONS in Regenerative Medicine. SPI-
ONS are particularly useful and have a multifunctional
aspect within regenerative medicine where their functions
include tagging, tracking, and activation of stem cells both in
vitro and in vivo;this multifunctionality makes them highly
desirable tools in this field.
1.3.1. Tagging. Incorporating SPIONs into cells allows for
the remote manipulation of cells using an external magnetic
field gradient. This encourages the precise positioning or
targeting of cells to desired sites for tissue regeneration or
repair [45, 46], allowing them to function as a powerful,
noninvasive tool in stem cell therapy [47, 48].
1.3.2. Tracking. A universal issue central to all cell-based
therapies is the in vivo migration of stem cells within tissues
and on substrates, which is often guided by the presence
of chemical mediators and material topography [49]. The
migration of these cells to and from the target location
requires precise monitoring to determine the eﬀectiveness of
the therapy. The use of nanoparticles can provide answers
to questions such as optimal delivery route; extent of
engraftment; migratory patterns after transplantation; ideal
dosage schemes. Having the answer to these questions will
help in the optimisation of the overall therapy and thus
increase its therapeutic potential [50]. It is thought that
MNP can be employed in conjunction with the use of
magnetic resonance imaging (MRI) to track implanted cells
in vivo (Figure 1). In essence, stem cells are encouraged to
internalise iron-based MNP; in this way magnetic properties
are transferred to the cells. The intracellular iron essentially
disturbs the local magnetic field thus allowing cells to be
visualised as a lack of signal with MRI [51].
1.3.3. Activation. Mechanical stimulation can be used to
facilitate cell proliferation, diﬀerentiation, and migration of
stem cells [53]; physical forces include fluid flow, axial com-
pression, tension, and magnetism [54]. Biological responses
are achieved through the process of mechanotransduction,
whereby cells convert physiological mechanical stimuli into
biochemical signals to activate the biological response [55].
Using MNP functionalised with antibodies or peptides, it is
possible to attach SPIONS to specific mechanosensitive cell
surface receptors and ion channels. This has been shown
to result in membrane polarisation, receptor activation, and
subsequent downstream second messenger signals in hMSC
[56]. Using this technology it has been shown that it is
possible to promote an osteochondral phenotype of hMSC
and human osteoblasts in response to magnetic activation
using an external oscillating magnetic field [57, 58].
1.3.4. MNP-Mediated Transfection. The transfection of ther-
apeutic genes could play a pivotal role in regenerative
medicine. This technology allows the replacement of defec-
tive genes or addition of extra copies of therapeutic genes
that are known to play a crucial part in the regeneration
of tissue. One example is the treatment of ischemia by
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transfecting human umbilical vein endothelial cells with
vascular endothelial growth factor to promote upregulation
of survival factors and subsequent improved cell viability
[59]. There are many mechanisms of inserting exogenous
genetic material into cells. Transfection with viruses can
be an eﬀective technique but there are safety and eﬃcacy
concerns with this strategy. Nonviral transfection methods,
for example, electroporation, transfection reagents, are con-
sidered safer. However these mechanisms often suﬀer from
poor transfection eﬃciency or impact on cell viability to
unacceptable levels depending on cell type. Therefore, a
stable, high transfection system with minimised toxicity that
can successfully deliver genes of interest without compro-
mising gene function is required [60]. MNPs are currently
being considered as alternate gene delivery vehicles; coated
with nucleic acid MNPs have shown the capacity to further
increase transfection eﬃciencies using magnetic fields to
attract the MNP towards the cell membrane; the particles
are then taken up by the cells by various uptake mechanisms
such as endocytosis. Upon uptake the DNA dissociates from
the nanoparticle and can then be expressed. One study has
successfully transfected theMG63 cell line without anymajor
eﬀects on cell viability [61].
To summarise, all three applications require the labelling
of stem cells with SPIONs. This can be achieved through
either the internalisation of SPIONs or the binding of
SPIONS to cell surface markers, for example, integrins, or
to specific antibodies [50, 62, 63].
2. Safety and Biocompatibility of
Magnetic Nanoparticles
Toxicity issues are a major concern and are important factors
in the context of regenerative medicine and tissue engineer-
ing. As mentioned previously, the use of MNPs in regenera-
tive medicine requires the labelling of cells (the therapeutic
agents) with MNPs which may then be implanted within
the body. Employing particles which are toxic in nature
over a long period of time can significantly diminish the
therapeutic eﬃciency of the cell-based therapy [38]. It is
valid at this point to state that toxicology is defined as the
study of adverse eﬀects of chemical, physical, and biological
agents in people, animals, and the environment [64]. Toxic
cellular eﬀects are translated into impaired mitochondrial
activity, membrane leakage, andmorphological changes.This
can have adverse eﬀects on cell viability, proliferation, and
metabolic activity and impair the therapeutic eﬃciency of
the therapy [65]. In cases where the MNPs are incorporated
into the therapy and transplanted within the body, the risk
of MNPs migrating through the organism, entering, and
accumulating within organs is a constant concern. This could
trigger an immunological or an inflammatory response
by the body [2, 17, 64]. These are all highly undesirable
consequences. Labelling stem cells for this application
therefore demands the preservation of physiological cellular
properties and the retention ofMNPs over prolonged periods
[66]. This formulates the following question: would any of
the properties related to MNPs indicated for regenerative
medicinal use provoke an adverse eﬀect on either the cells
(in vitro applications) or the body (in vivo applications)?
The toxicity of MNPs on biological entities is highly
dependent on a range and combination of factors related
to the properties of the MNP itself; structural properties,
dosage, and the intended use are among dominating factors
[38, 64]. The chemical composition of the particles them-
selves can be naturally toxic. Interestingly, some materials
which are known to be inert in large quantities are in fact
toxic at nanoscale, such as gold [64]. It has been found
that certain metals such as cobalt, nickel, cadmium, zinc,
and silver are toxic to biological entities and therefore
not suitable for biomedical applications while others such
as titanium and iron oxide-based particles are considered
significantly less damaging to cells [17, 30, 33]. In the case
of cadmium selenide (CdSe), cadmium ions demonstrated
to cause cell death in primary hepatocytes [38]. Additionally
the location of MNPs in relation to the cells is an extremely
important consideration [38]. For instance, MNPs could
invoke a cytotoxic response when internalised by potentially
interfering with the biological function of the cells but not
when attached to the cell membrane [11, 38]. In other
cases however, SPIONs attached to the surface of cells may
interfere with cell surface interaction [11]. Furthermore,
the physical properties such as the particle size, shape, and
surface coating can also evoke a toxic response by aggregating
and coagulating according to size and shape [38, 64]. When
addressing the possible in vivo application of MNP, it is
equally important to consider the fate of the MNPs after they
have been released by the cells. Further issues arise when
considering the degradation of the MNPs and the outcome
of accumulated MNPs or MNP by-products in various
tissues and organs [2]. Degradation products are thought
to possibly react with various components of the body or
cells. Therefore, the eﬀects of the breakdown products on
the surrounding tissue should be fully investigated [2, 29].
Therefore assumptions on this matter cannot be made, and
appropriate investigations should always be performed.
At the cellular level, oxidative stress is thought to be the
main cause of toxicity by MNPs [40]. Oxidative stress arises
when there is an imbalance between damaging oxidants also
referred to as reactive oxygen species (ROS) such as hydrogen
peroxide, hydroxyl radicals, and the protective antioxidants
of which vitamin C and glutathione are examples. ROS are
primarily formed by the incomplete reduction of oxygen [67]
The accumulation of oxidants eventually leads to destruction
of cellular proteins, enzymes, lipids, and nucleic acids, and
as a consequence the normal cellular processes become
impaired leading to the development of diseases and cell
apoptosis and necrosis [17, 23, 40, 67]. ROS can be generated
from the surface of MNP, the leaching of metal ions from
the core, or release of oxidants by enzymatic degradation
of the MNP [2]. ROS production can be measured using
dichlorofluorescein diacetate fluorescent probe after SPION
administration [65]. It has been reported that dissociated
iron oxide MNP can promote the formation of ROS and
hydroxyl radicals, and as a result may lead to cellular
toxicity along with impaired cell metabolism and increases in
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apoptosis [11]. On the other hand, ROS can be used in cancer
therapies to destroy damaging cancer, for example [67].
3. Studies
Years of research have demonstrated the ability of SPIONs to
be taken up by a wide variety of cells by simple incubation.
Cell types include fibroblasts, lung cells, liver cells, stem cells,
kidney cells, macrophages, nerve cells, endothelial cells, and
various cancer cells lines [2]. There is also an impressive
portfolio of MNPs that have been used with a variety of cell
types. The degree of toxicity has been known to vary with
cell type, MNPs, and a combination of these two factors. It
is therefore essential to carry out toxicity studies to evaluate
the toxicity of specific MNP on the particular cell type of
interest [29]. For instance, it has been reported that uncoated
SPIONS caused significant cell death in dermal fibroblasts
while lung cells appeared not to be aﬀected [2]. This high-
lights the importance of cell type and MNP relationship. The
general consensus is that labelling cells with SPIONs is safe
validated by the viability, proliferation, and diﬀerentiation
capacity of cells being unaﬀected thus justifying its use in
regenerative medicine [20, 29]. Other studies have shown
that internalised silica-coated magnetic nanoparticles are
biocompatible with stem cells [38]. Silica is a particular ben-
eficial coating for nanoparticles since it can easily be func-
tionalised, and it is resistant to degradation within a cellular
environment whilst still being biocompatible [38, 40].
Toxicity is investigated through a series of in vitro and
in vivo experiments, following the general schema below
(Figure 2). In vitro toxicity tests oﬀer a quick and simple
means of gathering preliminary toxicity data which is
also cost eﬀective with minimal ethical issues [17]. When
carrying out in vitro investigations, it is essential to identify
and apply reproducible in vivo environments in terms of
expanding conditions and sample preparation in vitro [2].
Data revealing marginal or no toxicity via in vitro tests can
then be moved onto in vivo studies [68]. In these situations,
small animal experiments are carried out and monitored
over time to investigate the long-term eﬀects of MNPs in a
biological setting. Toxicity validation tests include histology
on injection sites and major metabolic sites (liver, pancreas,
kidney, brain) to look for signs of MNP spreading and
accumulation. Sections are stained for iron by prussian blue
stain and caspase 3 as an indicator for apoptosis within these
areas [69]. It is not unlikely to have contradicting in vitro
and in vivo results. This may be attributed to in vivo bodily
functions/processes such as homeostasis, working to expel
foreign reagents which are not present in vitro, for example,
kidneys acting to filter blood [17]. Should in vivo studies
reveal encouraging results, both the therapeutic eﬃciency
and the safety of the MNP can be fully evaluated, and the
MNP treatment will have to be approved for clinical use by
regulatory bodies such as the Food and Drug Agency (FDA).
This requires human clinical trials. An important question is
whether the particles are regulated in combination with the
therapy or independently. This question highlights the fact
that the regulatory framework relating to these particles is
limited, thus making it diﬃcult to evaluate the safety of the
Cell interations Small animal 
work 
Clinical trials
Human trials
Regulatory 
approval
FDA, EMEA
In vitro tests In vivo tests
Figure 2: Schematic highlighting the route of translating stem cell-
based therapies (incorporating the use of MNP) from bench to bed
side.
nanomaterials in conjunction with regenerative medicine.
For this reason, extensive safety assessment of these particles
must be carried out to satisfy not only the regulators but
also the patient. Even though SPION-based MRI contrast
agents have been used and approved, the use of these for
stem cell-based therapies still requires FDA approval as their
intended use is diﬀerent from their use as contrast agents
[36]. An essential requirement of contrast agents is to be
excreted relatively quickly and not remain in the body in the
long term. However, for some applications, especially within
the remit of regenerative medicine, long-term treatment of
MNPs and presence in the body may be necessary. Using
FDA-approved contrast agents will however make this task
easier [66].
Table 1 highlights commonly used in vitro tests for MNP-
mediated toxicity and cell viability. It can be concluded
that MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide), PI (Propidium Iodide), for example,
live/dead assay [70] and trypan blue [71] stains are most
commonly used. Other popular tests not mentioned in
this table include BrdU (5-bromo-2′-deoxyuridine) assay
and the LDH (Lactate dehydrogenase) assay for metabolic
activity [10]. Toxicity assays are aimed at investigating vital
cellular activity such as cell death and cell viability. Cell
death or apoptosis is most commonly assessed using the
tetrazolium compound MTT [72, 73], LDH [74], and PI
[75] assay while cell proliferation is assessd using BrdU
[76] and MTT [73]. Figure 3 describes each test in greater
detail. Other notable cytotoxicity assays include cell-life cycle
assay, TUNEL assay (i.e., for apoptosis detection) [77], and
various redox assays [78]. Immunochemistry can also be
performed to look for markers of apoptosis or necrosis [79].
Furthermore, many toxic eﬀects caused by MNP may stop
mitochondrial activity which is measured by assays such as
MTT. Added to this, there are inherent issues associated
with MNP-cell interaction, dosage, and time course, all
of which may impact on results [79]. It should be noted
that in vitro tests that produce specific and quantitative
toxicity read-outs are particularly convenient for the initial
evaluation of toxicity and biocompatibility of newMNP [79].
An important consideration when interpreting the results of
these types of in vitro assays is that they often provide little
information on the mechanism of toxicity or the cause of cell
death. In addition it can be noticed that SPIONs do not aﬀect
cell viability, proliferation, or diﬀerentiation capacity of stem
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A dye exclusion test used to determine cell 
the properties of intact cell membrane. Dead or 
dying cells take up the dye. 
PI assay
LDH assay
MTT assay
Trypan blue
viability. Live cells exclude trypan blue due to
BrdU assay
The tetrazolium compound
MTT is reduced  
by metabolically active cells 
to formazan which forms
purple dye crystals.
Crystals are solubilised
and the absorbance read
using a spectrophotometer.
Evaluation of plasma membrane
damage. Lactate dehydrogenase
(LDH) is an enzyme, present in all
cells, and rapidly released upon
damage of the cell membrane.
LDH oxidizes lactate to generate
NADH which then reacts with WST to
generate a yellow compound in solution.
Absorbance is directly proportional
to the number of dead/dying cells
A fluorescent cell viability assay based
on the simultaneous determination of live 
and dead cells. Based on the measurement
of intracellular esterase activity and plasma
membrane integrity.
Live cells have intracellular esterase activity
and enzymatically convert the cell-permeant  
calcein AM dye to fluorescent calcein.  
EthD-1 enters cells with damaged membranes, 
binds to nucleic acids and increases fluorescence.
BrdU is incorporated into DNA during
proliferation. This is measured colorimetrically
and is proportional to the quantity of BrdU
incorporated into cells and therefore is an
indication of cell proliferation
Figure 3: Overview of in vitro toxicity assays. Cell image adapted from [2]. PI [75], MTT [72, 73], LDH [59], Trypan Blue [71] and BrdU
[76].
cells. In fact it can be said that number of studies reporting
adverse or toxic eﬀects of MNP are few [17].
Despite cost, time, and ethical considerations, in vivo
tests in relevant animal models are crucial for the study
of biological eﬀects that cannot be modelled in vitro. This
includes the pharmacokinetics of MNP in the body, that
is, absorption, distribution, metabolism, and elimination.
These studies allow information about the systemic toxicities
to be elucidated including immunological, neurological,
reproductive, cardiovascular, reproductive, and developmen-
tal as well as any carcinogenic eﬀects [79].
As far as in vivo assays are concerned, one of the
important functions to assess is the blood contact properties
of the MNP, that is, blood compatibility. In terms of in
vivo application of MNP, should the MNP be incompatible
with bio fluids such as blood, this could lead to haemolysis,
coagulation, and blood clots due to adsorption and/or
activation of biomolecules, for example, plasma protein,
complement factors, and so forth. As such it is critical to
assess these properties before clinical use. One such test is
the haemolysis assay which uses erythrocytes to assess the
MNP toxicity. The coagulation tendencies can be assessed
using common clinical assays including prothrombin time
(PT), activated clotting time (ACT), and activated partial
thromboplastin time (APTT) [79]. Another parameter to
assess is the inflammatory response. This can be evaluated
by looking at levels of chemokines and proinflammatory
cytokines, for example, IL-8 in the blood as these can indicate
potential oxidative stress toxic eﬀects caused by MNP [34].
Gene expression analysis for transcription factors associated
with oxidative stress can also be examined and may reveal
useful information about the mechanism of toxicity. This
raises the possibility of correlating MNP characteristics with
toxic eﬀects observed in certain cell lines and tissues [79].
Once the MNPs have entered body, MNPs come into
direct contact with biological macromolecules such as pro-
teins, lipids, and enzymes found within the biological fluid.
These biomolecules interact with the surface of the MNP
to form a complex layer of molecules over the MNP. This
biological layer is termed “corona” [80, 81]. The physical
and chemical properties of MNP (size, surface coating, and
functionalization) dictate the binding of molecules to the
particles resulting in either a hard or weak corona which
is significantly diﬀerent to that of the surface of the MNP
[80, 81]. This aﬀects the initial interaction of the cell with
the MNP as the cell’s first point of contact is with the corona
and not the surface of the particle [80]. In turn, this dictates
subsequent cellular and tissue responses [81]. This protein
corona could be responsible for various toxic outcomes [80].
The formation of the corona is a dynamic process, and com-
petitive process involving the attachment and detachment of
various proteins as the particle moves from one biological
8 Journal of Nanomaterials
environment to another [81] Movement of particles from
one biological environment to another causes proteins from
original fluid to be replaced by proteins from new fluid—
leaving evidence of the previously attached proteins [80, 81].
Approximately 10–50 proteins with the highest aﬃnity for
the surface are bound at one time [81]. The parameters
aﬀecting MNP-protein interaction include physiochemical
properties (such as surface chemistries, particle size, shape,
charge, surface area, surface defects, smoothness/ roughness,
and functional groups) of MNP and the composition of
biological fluid (proteins types and ratios) [81].
The interaction of proteins with the surface of MNPs
of diﬀerent types and coatings is also an important con-
sideration when assessing in vitro toxicity. When MNPs are
added to culture media, media proteins and other nutrients
may adsorb onto MNPs and thus are unavailable for cellular
activities. This naturally has implications on cell growth and
viability. It is paramount therefore to test diﬀerent culture
media as MNP-protein interaction is dependent on the in
vitro environment andMNP composition, so diﬀerent media
recipes could influence the outcome of cytotoxicity assays
[78, 82].
A related concept is the eﬀect of “cell vision” presented by
Laurent et al. [82]. This refers to the contact point between
MNP and the cell membrane, which is characterised by its
surface molecules, that is, proteins, sugars, and phospholipid
composition. The binding of MNP to these structures
which may be diﬀerent for diﬀerent cell types defines how
individual cell lines “see” MNPs. As a result the binding of
exogenous objects like MNP to these structures may cause
diﬀerent responses and influence uptake and metabolism
depending on the cell type. This concept is exemplified by
Laurent et al. who showed that the same concentration of
SPIONS can cause significant toxicity on neuronal and glial
cells whilst displaying little toxicity on other cell types like
heart and kidney cells [82, 83]. The issues of cell vision and
MNP-media interactions raise questions about the reliability
of toxicity assays when studying the toxic eﬀects of MNP.
This issue is highlighted by the seemingly contradictory
results of some MNP toxicity assays [34]. To address this
issue Mahmoudi et al. have modified the MTT protocol by
exposing SPIONS to culture media thereby allowing MNP
to interact with culture media proteins before adding them
to cell cultures. This led to improvements in the reliability
of in vitro MNP toxicity results. Their results showed that
uncoated and coated SPIONs were less toxic as previously
thought and induced toxicity in various cell lines at greater
doses than permitted for humans [78]. Furthermore another
problem is posed by the sedimentation of MNPs, as this
phenomenon eﬀectively leads to an apparent increase in
MNP concentration at the cell surface and so should be taken
into account when performing toxicity assays [82].
4. Conclusion and Future Perspectives
It has been mentioned that in vitro and in vivo toxicity
results often contradict each other. This can be attributed to
the issue of protein adsorption onto the surface of MNP. It
has also been suggested that various biomaterials intended
for biological/tissue engineering purposes may benefit from
exposure to biological fluids prior to implantation. This
would allow for a layer of preadsorbed proteins to adhere on
the surface of thematerial whichmay oﬀer several advantages
in terms of cellular mediated responses [84]. Following this
theory, in vivo toxicity studies could be mimicked to a closer
extent in vitro with the MNP in question when exposed to
the desired biological fluid.
The multifunctional applications of MNP have been
established. However utilizing micro- or nanoporous struc-
tures with nanometer superparamagnetic particles embed-
ded within this structure could oﬀer an alternative means
of activating and inducing diﬀerentiation of stem cells
for tissue engineering in vivo. Various biocompatible and
bioactive materials have been used to fabricate these porous
structures and have had impressive results in terms of cellular
compatibility and diﬀerentiation in terms of osteogenesis
and chondrogenesis [84, 85]. Examples of such porous
nanoparticles include nickel titanium nanoparticles coated
with titanium oxide [85] and calcium phosphate ceramics
[84]. Preexposing nanoparticles to solutions of specific
proteins could also warrant increased cell attachment, pro-
liferations, and the diﬀerentiation of stem cells down various
lineages such as osteogenic or chondrogenic pathways [84,
85]. Thus combing the use of biocompatible materials
known to promote or induce diﬀerentiation with magnetic
properties could be of great benefit in tissue engineering and
regenerative medicine.
This paper has addressed the relevance of MNP in regen-
erative medicine, highlighting their diverse and significant
applications within this field. MNPs oﬀer a noninvasive,
practical means of monitoring, controlling, and targeting
stem cells to optimise the therapy with clinical adoption
in mind. However, safety concerns could ultimately prevent
the adoption of MNP in regenerative medicine. This would
demand the development of alternative ways of monitoring
and controlling stem cells in vivo. It is essential to confirm
the safety of the procedure prior to in vivo transplantation
despite clinical eﬃcacy of the technique. In reality, there is an
enormous portfolio of particles available both commercially
and in research. This makes it very diﬃcult to give a definitive
answer to the following question: are MNPs toxic? The
toxic eﬀects of MNPs should be evaluated for each specific
purpose. A large number of in vitro toxicity investigations
have shown no adverse side eﬀect of labelling stem cells with
SPIONs. However, long-term in vivo studies have not been
studied as extensively and hence are an area of much needed
research.
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